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Abstract
Background: Primary myelofibrosis (PMF) is a type of myeloproliferative neoplasm (MPN) characterized by the
predominant proliferation of megakaryocytes and granulocytes in the bone marrow, leading to the deposition of
fibrous tissue, and by a propensity toward extramedullary hematopoiesis. Renal involvement in PMF is rare, but
kidney tissue samples from these patients reveal MPN-related glomerulopathy, a recently discovered condition, in
the late stages of the disease.
Case presentation: We present the first case described in the medical literature of a patient with early renal
glomerular involvement in PMF/MPN. A 60-year-old man with stage 4 chronic kidney disease and a recent
diagnosis of PMF (within 4 weeks of presentation at our renal division) presented with generalized body swelling,
acute kidney injury, and massive nephrotic-range proteinuria. Kidney biopsy was performed to determine the
etiology of the patient’s renal dysfunction and revealed early renal glomerular involvement that was histologically
characteristic of MPN-related glomerulopathy. Early diagnosis and prompt medical management returned the
patient’s kidney functionality to the levels seen on initial presentation at our hospital.
Conclusion: Large studies with long follow-up durations are necessary to identify and categorize the risk factors for
the development of MPN-related glomerulopathy, to standardize therapeutic regimens, and to determine whether
aggressive management of the myelofibrosis slows the progression of kidney disease.
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Background
Myeloproliferative neoplasms (MPNs) are clonal
hematopoietic stem cell disorders in which proliferation of
one or more of the myeloid lineages occurs owing to ac-
quired somatic mutations in signal transduction pathways,
which results in fibrosis of the bone marrow. MPNs gener-
ally occur in the elderly [1]. Primary myelofibrosis (PMF),
a type of MPN, is defined by the predominant prolifera-
tion of megakaryocytes and granulocytes in the bone mar-
row, eventually leading to the deposition of fibrous tissue
with progressive pancytopenia, and by a propensity toward
extramedullary hematopoiesis, including enlargement of
the liver and spleen [2]. The major complications associ-
ated with MPN disease include increased risk of
thrombosis and hemorrhage and transformation into
acute myeloid leukemia [3]. Renal involvement in
MPN is infrequent. Acute kidney injury may develop
because thrombosis of the renal vessels , occlusion of
the urinary tract by blood clots, tumor lysis syndrome,
or due to leukemic infiltration of the interstitium [4, 5].
Patients with MPN develop a distinct glomerular lesion,
recently described as MPN-related glomerulopathy, which
differs in morphology and pathology from those caused by
other hematologic neoplasms [4, 6]. MPN-related glomer-
ulopathy is the first glomerular injury that has been associ-
ated with myeloid neoplasms [7]. Typical clinical
presentation includes nephrotic-range proteinuria (with or
without the full nephrotic syndrome) and chronic renal
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insufficiency. Diagnosis is confirmed by kidney biopsy; tis-
sue samples show the histopathological pattern associated
with MPN-related glomerulopathy comprising variaing
degrees of mesangial hypercellularity and sclerosis, seg-
mental sclerosis, and intracapillary hematopoietic cell
infiltration (most commonly with megakaryocytes) on
light microscopy and absence of immune deposits on im-
munofluorescence and electron microscopy. Additionally,
segmental subendothelial electron-lucent thickening with
glomerular basement membrane double contours is seen
in some patients, mimicking a chronic thrombotic micro-
angiopathy [7].
Proper recognition of MPN-related glomerulopathy and
differentiation of this renal disorder from other forms of
sclerosing glomerulopathy, thrombotic microangiopathy,
and immune-complex glomerulonephritis are essential for
diagnosis and management. We describe the first case in
the medical literature of an early manifestation of MPN-
related glomerulopathy in a patient recently diagnosed
with PMF, and significant improvement in kidney function
upon successful therapy of PMF with ruxolitinib, an oral
JAK inhibitor.
Case report
A 60-year-old white man with stage 4 chronic kidney
disease (CKD), coronary artery disease, hypertension, dys-
lipidemia, and a recent diagnosis of PMF presented at our
renal division with generalized body swelling and an ele-
vated serum creatinine level with massive nephrotic-range
proteinuria. His serum creatinine level was 1.78 mg/dL at
the initial consultation at our institution. He was a former
smoker of 35 pack-years.
The examination revealed diminished bibasilar breath
sounds and severe abdominal distension with massive
hepatosplenomegaly along with profound anasarca. No skin
rashes were seen. Laboratory work-up revealed thrombocy-
tosis, hyperlipidemia, and hypoalbuminemia. Urinalysis re-
vealed proteinuria at 600 mg/dL and 300 mg/dL of glucose,
and the spot urine sample had a protein to creatinine ratio
of 23 along with multiple granular casts. The estimated
glomerular filtration rate was 27 mL/min/1.73 m2 (normal
range, 90–120 mL/min/1.73 m2).
Given his massive proteinuria, hypoalbuminemia, and
peripheral edema, the differential diagnoses included focal
segmental glomerulosclerosis (secondary to myelofibrosis),
membranous glomerulonephritis, amyloidosis, and para-
neoplastic glomerulonephritis. Results from the protein-
uria assessment and work-up with serum and urine
protein electrophoresis, immunofixation, hepatitis and
human immunodeficiency virus tests, and tests for antinu-
clear antibodies and other immunological markers were
unremarkable. Transthoracic echocardiography images
showed no valvular abnormalities, and the patient had an
ejection fraction of 60 % (normal value > 55 %).
The patient was placed on a salt and fluid restricted diet
and was treated with bumetanide, lisinopril, hydralazine,
carvedilol, isosorbide mononitrate, and rosuvastatin. He
was on hydroxyurea for PMF. He underwent a kidney
biopsy (less than 30 days from his initial diagnosis of PMF
and nephrotic syndrome) to determine the etiology of his
massive proteinuria and further worsening kidney injury.
The patient’s symptoms improved with treatment over
the next 2 weeks, with a reduction in body swelling and ab-
dominal distension. Therapy with a new JAK inhibitor (rux-
olitinib) was started; after 4 months of treatment, the
patient’s white blood cell count decreased from 61,000 K/ul
to 12,000 K/ul and platelets from 1152,000 K/ul, to normal
levels, decrease in splenomegaly from 13 cm to 4 cm, and
hepatomegaly from 14 cm to non-palpable,. This was ac-
companied with a decrease in his protein to creatinine ratio
to 8 g from 23 g and return of his baseline creatinine to
1.78 mg/dL from a peak value of 4.23 mg/dL.
Kidney biopsy
Light microscopic examination of the kidney tissue
(Fig. 1a-c) revealed twelve glomeruli which were
slightly enlarged with diffuse mesangial matrix ex-
pansion and mild mesangial hypercellularity; how-
ever, the segmental capillaries also contained cells
with large atypical-appearing nuclei consistent with
megakaryocytes. The expanded mesangial matrix
stained positive for periodic acid-Schiff and Grocott
methenamine silver. One glomerulus was globally
sclerotic and no glomerulus was segmentally scler-
otic. There was a diffuse mild to moderate increase
in tubulointerstitial matrix, but without tubular atro-
phy. Only a scant mononuclear inflammatory infil-
trate was present. Tubules were mildly ectatic focally
with loss of brush borders. Interstitial capillaries also
contained occasional megakaryocytes. Mild to mod-
erate arteriosclerosis with focal hyaline arteriolar
sclerosis was present. Immunofluorescence showed
weak to 1+ mesangial IgM, but glomeruli were nega-
tive for IgG, IgA, kappa light chain, lambda light
chain, C3 and C1q. Electron microscopic examin-
ation of three glomeruli (Fig. 2) revealed diffuse,
moderate expansion of the mesangial matrix with
very focal segmental deposits of slightly electron- dense
material, but typical immune complex deposits were not
present. Occasional megakaryocytes with characteristic
small dense core granules and immature myeloid-series
cells were seen within the capillaries. Podocyte foot pro-
cesses were extensively effaced.
Liver biopsy
A liver biopsy, performed at the same time as the kidney bi-
opsy (Fig. 1d) showed extramedullary hematopoiesis char-
acterized by dilated sinusoids which contained moderate
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amount of immature myeloid cells including megakaryo-
cytes, nucleated red blood cells, and myelocytes in various
stages of maturation and differentiation.
Discussion
The morphological differential diagnosis of MPN-related
glomerulopathy includes diabetic glomerulosclerosis, smok-
ing-related glomerulopathy, primary focal segmental glo-
merulosclerosis, thrombotic microangiopathy, and chronic
membranoproliferative glomerulonephritis. Mesangial
hypercellularity is more prominent in MPN-related
glomerulopathy than in diabetic glomerulosclerosis,
smoking-related glomerulopathy, and primary focal seg-
mental glomerulosclerosis, whereas nodular mesangial
sclerosis is not typically associated with MPN-related glo-
merulopathy. Absence of immune deposits revealed by im-
munofluorescence and electron microscopy differentiates
MPN-related glomerulopathy from membranoproliferative
Fig. 1 Microscopy results of kidney and liver tissue from a 60-year-old man with myeloproliferative neoplasm-related glomerulopathy in the
early stages of primary myelofibrosis hematoxylin and eosin (H&E) (a) and periodic acid-Schiff (PAS) (b) stained sections of glomeruli with
moderate mesangial matrix expansion and occasional intracapillary and intra-arteriolar megakaryocytes (arrows). The renal tubulointerstitium
(c) also contained interstitial or intracapillary megakaryocytes (arrow). A biopsy of the liver (d) showed megakaryocytes, nucleated red blood
cells and other immature myeloid cell within the hepatic sinusoids
Fig. 2 Electron micrographs show glomeruli with segmental intracapillary megakaryocytes (a and b) and mesangial matrix expansion (a).
Podocyte foot processes were extensively effaced. Megakaryocytes contained characteristic small dense core granules (arrows) and multilobular
nuclei (b)
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glomerulonephritis [7]. Though it is well known that the
myeloproliferation in MPN results from a clonal expansion
of the myeloid progenitor cells, the subsequent myelofibro-
sis definitive of PMF is hypothesized to be due to a reactive
mechanism mediated by megakaryocyte-derived excessive
synthesis of growth factors including platelet-derived
growth factor and transforming growth factor-β [8, 9].
Platelet-derived growth factor stimulates mesangial cell pro-
liferation, mesangial matrix synthesis, and apoptosis of
podocytes, whereas transforming growth factor-β aids in
mesangial cell production of collagen and fibronectin. The
combination of these effects could cause glomerular le-
sions specific to MPN-related nephropathy. Further-
more, aggregation of circulating hematopoietic cells
within glomerular presumably capillaries could pre-
sumably lead to endothelial injury and morphological
changes mimicking chronic thrombotic microangiopa-
thy [10, 11].
In a recent series of 11 patients with MPN who devel-
oped proteinuria and renal insufficiency, most of the
patients (73 %) had PMF, a less prevalent type of MPN,
suggesting that patients with PMF have a higher risk of
developing MPN-related glomerulopathy than do patients
with other types of MPN [7]. However, PMF is not consid-
ered a pure paraneoplastic disease because of the presence
of hematopoietic cell infiltration. In these 11 patients, the
clinical manifestations of MPN-related glomerulopathy,
namely proteinuria of greater than 3 g/day with chronic
renal insufficiency, tended to manifest late in the course of
MPN (the mean time from diagnosis of MPN to kidney
biopsy was 7.2 years) [7].
In a recent study, the frequency of CKD in a large
cohort of 143 MPN patients from Denmark at time of
diagnosis was 29 %: 27 % had stage 3 CKD, and 2 % had
stage 4 CKD. This was the first study to describe the
progression patterns in renal function over time in MPN
patients [12]. This important and speculative finding of
a high frequency of CKD at diagnosis of MPN suggests
that MPN disease detrimentally affects kidney function.
In this context, MPN and CKD could be linked by
chronic inflammation, which is hypothesized to be a
trigger and amplifier of the MPN disease process [13].
The prognosis of patients with MPN-related glomeru-
lopathy, unlike those with other glomerulopathies,
remains guarded even after corticosteroid therapy,
renin-angiotensin system blockade, and treatment of the
underlying neoplasm [7]. Most patients continue to
have persistent renal dysfunction with progression to
end-stage renal disease, and therefore it was very satis-
fying to witness significant clinical improvement in
patient’s condition and renal function on therapy with
JAK inhibitor, ruxolitinib. Because PMF and MPN-
related glomerulopathy were detected within a relatively
short time in our patient, prompt medical management
restored stable renal function. However, because our pa-
tient also has stage 4 CKD and multiple co-morbidities,
his long-term prognosis remains poor.
Conclusions
Larger studies with longer follow-up durations are ne-
cessary to identify and categorize the risk factors for
the development of MPN-related glomerulopathy, to
standardize therapeutic regimens, and to determine
whether aggressive management of the myelofibrosis
slows the progression of kidney disease. We recom-
mend that patients with hematological neoplasms
should be screened for urinary abnormalities, espe-
cially proteinuria. An aggressive approach to urinary
screening and kidney biopsy would provide more data
on the frequency and course of renal disease in MPN
and would provide key information on the feasibility
of conducting clinical trials for treating MPN-related
glomerulopathy.
Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompany-
ing images. A copy of the written consent is available for
review by the Editor of this journal.
Abbreviations
CKD: Chronic Kidney Disease; MPN: Myeloproliferative Neoplasm;
PMF: Primary Myelofibrosis.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AR: Collected the data needed and helped in writing the manuscript.
TN: Helped in writing the manuscript. MA: Provided valuable input to
structure of manuscript and helped in writing. WG: Provided his
expertise, written the pathological findings and edited paper. AP: Helped
in writing the discussion. SV: Provide his expertise as the primary
oncologist and helped in writing and editing the paper. AA: Helped in
writing and final editing the paper. Overlooked everyone contributions
and finalized the manuscript. All authors have equally contributed to
this work and approved the final manuscript.
Acknowledgements
We thank Jill R Delsigne who provided medical writing services on behalf of
The University of Texas MD Anderson Cancer Center.
Author details
1Department of Internal Medicine, The University of Texas MD Anderson
Cancer Center, Houston, TX, USA. 2Department of Nephrology, The University
of Texas Medical School at Houston, Houston, TX, USA. 3Division of Medical
Oncology, Duke University School of Medicine, Durham, NC, USA.
4Department of Renal Pathology, The University of Texas Medical School at
Houston, Houston, TX, USA. 5Department of Leukemia, The University of
Texas MD Anderson Cancer Center, Houston, TX, USA. 6Division of Internal
Medicine, Section of Nephrology, The University of Texas MD Anderson
Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.
Received: 16 March 2015 Accepted: 23 July 2015
Rajasekaran et al. BMC Nephrology  (2015) 16:121 Page 4 of 5
References
1. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med.
2006;355(23):2452–66.
2. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative
neoplasms: the 2008 World Health Organization criteria and point-of-care
diagnostic algorithms. Leukemia. 2008;22(1):14–22.
3. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera
and essential thrombocythaemia. Br J Haematol. 2005;128(3):275–90.
4. Bello Nicolau I, Conde Zurita JM, Barrientos Guzman A, Gutierrez Millet V,
Ruilope Urioste LM, Prieto Carles C, et al. Essential thrombocytosis with
acute renal failure due to bilateral thrombosis of the renal arteries and
veins. Nephron. 1982;32(1):73–4.
5. Yuzawa Y, Sato W, Masuda T, Hamada Y, Tatematsu M, Yasuda Y, et al.
Acute kidney injury presenting a feature of leukemic infiltration during
therapy for chronic myelogenous leukemia. Intern Med.
2010;49(12):1139–42.
6. Bardy A, Tiple A, Rabant M, Kemeny JL, El Karoui K, Hermet M, et al. The
myeloproliferative neoplasms-related glomerulopathy. Rev Med Interne.
2014;35(4):222–30.
7. Said SM, Leung N, Sethi S, Cornell LD, Fidler ME, Grande JP, et al.
Myeloproliferative neoplasms cause glomerulopathy. Kidney Int.
2011;80(7):753–9.
8. Martyre MC. TGF-beta and megakaryocytes in the pathogenesis of
myelofibrosis in myeloproliferative disorders. Leuk Lymphoma.
1995;20(1–2):39–44.
9. Martyre MC, Magdelenat H, Bryckaert MC, Laine-Bidron C, Calvo F. Increased
intraplatelet levels of platelet-derived growth factor and transforming
growth factor-beta in patients with myelofibrosis with myeloid metaplasia.
Br J Haematol. 1991;77(1):80–6.
10. Floege J, Eitner F, Alpers CE. A new look at platelet-derived growth factor in
renal disease. J Am Soc Nephrol. 2008;19(1):12–23.
11. Jiang T, Che Q, Lin Y, Li H, Zhang N. Aldose reductase regulates TGF-beta1-
induced production of fibronectin and type IV collagen in cultured rat
mesangial cells. Nephrology (Carlton). 2006;11(2):105–12.
12. Christensen AS, Moller JB, Hasselbalch HC. Chronic kidney disease in
patients with the Philadelphia-negative chronic myeloproliferative
neoplasms. Leuk Res. 2014;38(4):490–5.
13. Hasselbalch HC. Perspectives on chronic inflammation in essential
thrombocythemia, polycythemia vera, and myelofibrosis: is chronic
inflammation a trigger and driver of clonal evolution and development of
accelerated atherosclerosis and second cancer? Blood. 2012;119(14):3219–25.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Rajasekaran et al. BMC Nephrology  (2015) 16:121 Page 5 of 5
